Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yeter Düzenli Kar is active.

Publication


Featured researches published by Yeter Düzenli Kar.


Drug discoveries and therapeutics | 2017

Beta blocker and steroid therapy in the treatment of infantile hepatic hemangioendothelioma

Zeynep Canan Özdemir; Yeter Düzenli Kar; Nurullah Cihan Şöhret; Mahmut Kebapci; Özcan Bör

Infantile hepatic hemangioendothelioma (IHHE) is the most common benign vascular liver tumor and typically occurs during the first 6 months of life. A 4-month-old male patient presented with abdominal distention. A physical examination revealed massive hepatomegaly. Liver enzyme levels were normal. The alpha fetoprotein level was 1,323 mg/dL (6-1,000). Abdominal magnetic resonance imaging (MRI) showed multiple, well-defined and hyperintense nodular lesions in the liver. MRI findings suggested IHHE. The thyroid stimulating hormone (TSH) level was high (177.2 µU/mL). He was started on sodium levothyroxine 50 μg daily. The patient has hypoxemia due to abdominal distention during the follow-up period. Oral methylprednisolone therapy was started at a dose of 2.5 mg/kg/dose, and propranolol at a dose of 1 mg/kg/dose, bid. Fifteen days later his TSH level remained elevated at 212.3 μU/mL despite repeatedly increasing the dose of levothyroxine up to 200 μg/daily. One month after the initial presentation, his TSH level was reduced to 11.28 µU/mL. We observed a marked improvement in abdominal distention and respiratory distress within 15 days and an average reduction of 50% in the lesion diameters after a month. Despite its benign nature, IHHE may lead to development of complications. Steroid and propranolol treatment may be useful in in the management of emergency complications.


International Journal of Pediatrics and Adolescent Medicine | 2016

The frequency of hepatotoxicity and myelotoxicity in leukemic children with different high doses of methotrexate

Zeynep Canan Özdemir; Ayşe Bozkurt Turhan; Yeter Düzenli Kar; Özcan Bör

Background and objectives Methotrexate (MTX) is a chemotherapeutic agent that functions as a folic acid antagonist. The frequency of high dose methotrexate (HDMTX)-associated toxicity is variable. In this study, we investigated the frequency of myelotoxicity and hepatotoxicity 7 days after HDMTX infusion. Patients and methods This study included children diagnosed with acute lymphoblastic leukemia (ALL) between January 2010 and April 2015. The patient blood counts and biochemical parameters measured before and after 7 days of HDMTX infusion were retrospectively recorded. We assessed HDMTX infusions for 48 children. The number of patients and drug doses included the following: 17 children receiving 1 g/m2 (68 infusions), 14 children receiving 2 g/m2 (56 infusions), and 17 children receiving 5 g/m2 (68 infusions). The classification of toxicity was made based on the Common Terminology Criteria for Adverse Events (CTCAE) 2010 criteria. Myelotoxicity was defined as a hemoglobin level <10 g/L and absolute neutrophil count <1 × 109/L or platelet count <75 × 109/L. The presence of transaminase levels ≥5 times the upper limit was considered to be hepatotoxicity grade ≥3. The MTX levels at 42 h in patients with and without toxicity were compared to evaluate the correlation between MTX levels, hematologic parameters, and transaminase levels. Results Myelotoxicity was observed in 35.2%, 37.5%, and 33.8% of the infusions, and hepatotoxicity grade ≥3 was detected in 13.2%, 12.5%, and 11.7% of the infusions in patients receiving 1, 2 and 5 g/m2 HDMTX after 7 days, respectively. There was no statistically significant difference between MTX levels at 42 h in patients with and without toxicity (P > .05, for all). There was no correlation between hematologic parameters and transaminase levels and MTX levels at 42 h. Conclusion Hematologic toxicity was the most common toxicity observed. The data indicate the hematologic toxicity increased after repeated cycles in patients receiving 5 g/m2. However, the hepatic toxicity decreased with additional cycles. Our results show the level of MTX at 42 h is not effective to identify toxicity.


Hematology | 2018

Evaluation of hypercoagulability with rotational thromboelastometry in children with iron deficiency anemia

Zeynep Canan Özdemir; Yeter Düzenli Kar; Eren Gündüz; Ayşe Bozkurt Turhan; Özcan Bör

ABSTRACT Objective: Iron deficiency anemia (IDA) has been demonstrated to be a risk factor for thromboembolic events, although the pathogenesis of the development of thromboembolism in IDA is as yet unclear. The likelihood of children with IDA contracting hypercoagulability was evaluated in this cross-sectional study using rotational thromboelastometry (ROTEM). Material and Method: A total of 57 children with IDA (median age 11 years; 37 female, 20 male) and 48 healthy children (median age 9.9 years; 23 female, 25 male) were enrolled in the study. Whole blood count, serum iron, transferrin saturation, ferritin level, prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen levels were ascertained, while ROTEM assays [intrinsic TEM (INTEM) and extrinsic TEM (EXTEM)] were used to measure and analyze coagulation time (CT), clot formation time (CFT), maximum clot firmness (MCF) and rate of maximum lysis (ML60%). This study conforms to ethical standards, has been approved by the appropriate Institutional Review Board. Results: Hemoglobin, serum iron, transferrin saturation and ferritin levels were lower in the IDA group than in the control group (p < 0.001, for all), while the EXTEM and INTEM CT in the two groups were similar (p > 0.05). The EXTEM and INTEM MCF in the IDA group was higher than in the control group, while the INTEM CFT and rate of ML60% were lower than in the control group (p < 0.001, p < 0.001, p < 0.05, p < 0.001, respectively). Conclusion: The ROTEM results suggest that although the platelet count and coagulation tests were within normal ranges in IDA, the tendency to coagulate may have been increased.


Turk Pediatri Arsivi-turkish Archives of Pediatrics | 2017

Evaluation of febrile neutropenic attacks of pediatric hematology-oncology patients with febrile neutropenia

Yeter Düzenli Kar; Zeynep Canan Özdemir; Özcan Bör

Aim Febrile neutropenia is an important cause of mortality and morbidity in hematology-oncology patients undergoing chemotherapy. The objective of this study was to evaluate febrile neutropenic episodes in children with malignancy. Material and Methods Sixty-eight children who received chemotherapy for malignancy between 2010 and 2015 were retrospectively reviewed. The demographic characteristics, laboratory data, infection foci, and frequency of microorganisms grown in culture were examined. Also, the frequency of febrile neutropenic attacks was investigated according to the chemotherapy periods. Results Of the total 200 episodes, 81 (40.5%) were clinically documented, and 73 (36.5%) were microbiologically documented infections. Fever of unknown origin was observed in 46 (23%) episodes. The most frequently clinically documented focus were mucositis (33.4%) and pneumonia (24.7%). Blood culture was positive in 55 (75.3%) episodes of microbiologically documented infections. The most commonly isolated microorganisms in blood culture were Gram-negative bacteria (47.2%). C-reactive protein levels in microbiologically documented infections were higher than in clinically documented infections, and fever of unknown origin (p<0.05, for both). The most common underlying malignancy was acute lymphoblastic leukemia (73.5%). The highest proportions (34.6%) of febrile neutropenic episodes were observed during the reinduction period for these children. Nine (13.2%) children died of neutropenic sepsis. Conclusions Febrile neutropenia continues to be an important cause of mortality in pediatric patients with malignancy. C-reactive protein levels may be an indicator for predicting bacterial infection in children with febrile neutropenia without apparent focus. The most frequently isolated agents in our center were Gram-negative microorganisms. Determining the microbial flora of each center may be beneficial to improving survival rates.


Pediatric Hematology and Oncology | 2017

Fatal course of Saprochaete capitata fungemia in children with acute lymphoblastic leukemia

Zeynep Canan Özdemir; Ayşe Bozkurt Turhan; Yeter Düzenli Kar; Çağrı Ener Dinleyici; Özcan Bör

ABSTRACT Saprochaete capitata (S. capitata) is a very rare fungal pathogen that causes disseminated opportunistic infections in patients with hematologic malignancies. Fever resistant to broad-spectrum antibiotic and antifungal treatment is common in the presence of fungemia during the period of profound neutropenia. We describe three cases of leukemic children who died from S. capitata fungemia following a first febrile neutropenic episode after the induction of chemotherapy. S. capitata fungemia is an emergent infection associated with high mortality and low susceptibility to fluconazole and echinocandins. Awareness of this emergent infection is needed to ensure that it can be properly treated.


Indian Pediatrics | 2017

Incomplete Miller—Fisher syndrome with advanced stage Burkitt lymphoma

Zeynep Canan Özdemir; Yeter Düzenli Kar; Coþkun Yarar; Suzan Þaylýsoy; Özcan Bör

BackgroundLymphoma-associated incomplete Miller-Fisher syndrome is very rare.Case CharacteristicsAn 11-year-old boy who initially presented with headache, left ptosis, diplopia and weakness. Neurologic examination indicated left sided ptosis with ophthalmoplegia.ObservationsCerebral imaging and cerebrospinal fluid examinations were normal. Magnetic resonance imaging of the abdomen showed a mass lesion in the ileal loops. A bone marrow biopsy showed infiltration by Burkitt’s lymphoma.MessageBurkitt lymphoma may present with incomplete Miller Fisher syndrome.


Turk Pediatri Arsivi-turkish Archives of Pediatrics | 2018

Evaluation of febrile neutropenic attacks of pediatric hematology-oncology patients

Yeter Düzenli Kar; Zeynep Canan Özdemir; Özcan Bör


Osmangazi Tıp Dergisi | 2018

Valproik Asitin Epileptik Çocuklarda Fetal Hemoglobin Sentezi Üzerine Etkileri

Kürşat Bora Çarman; Zeynep Canan Özdemir; Yeter Düzenli Kar; Eren Gündüz; Havva Üsküdar Teke; Didem Arslantas; Coskun Yarar; Özcan Bör


Journal of Pediatric Hematology Oncology | 2018

Hemophagocytic Lymphohystiocytosis Associated With Type Ia Glycogen Storage Disease

Yeter Düzenli Kar; Zeynep Canan Özdemir; Eylem Kiral; Gonca Kılıç Yıldırım; Ener Cagri Dinleyici; Özcan Bör


Turkiye Klinikleri Tip Bilimleri Dergisi | 2017

Folliküler Lenfoma Tanısı Konulan Nijmegen Kırık Sendromu

Yeter Düzenli Kar; Zeynep Canan Özdemir; Özcan Bör

Collaboration


Dive into the Yeter Düzenli Kar's collaboration.

Top Co-Authors

Avatar

Zeynep Canan Özdemir

Eskişehir Osmangazi University

View shared research outputs
Top Co-Authors

Avatar

Özcan Bör

Eskişehir Osmangazi University

View shared research outputs
Top Co-Authors

Avatar

Ayşe Bozkurt Turhan

Eskişehir Osmangazi University

View shared research outputs
Top Co-Authors

Avatar

Eren Gündüz

Eskişehir Osmangazi University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Didem Arslantas

Eskişehir Osmangazi University

View shared research outputs
Top Co-Authors

Avatar

Ener Cagri Dinleyici

Eskişehir Osmangazi University

View shared research outputs
Top Co-Authors

Avatar

Eylem Kiral

Eskişehir Osmangazi University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mahmut Kebapci

Eskişehir Osmangazi University

View shared research outputs
Researchain Logo
Decentralizing Knowledge